ATMP XB Project 

Introduction 

ATMP XB is a cross-border initiative focused on strengthening the QA/QC ecosystem for Advanced Therapy Medicinal Products (ATMPs) in the Flemish-Dutch region. By connecting key stakeholders, the project aims to accelerate the development and delivery of innovative therapies for patients with severe or life-threatening diseases. 

About the Project 

ATMP XB addresses critical challenges in the development and delivery of ATMPs. The project aims to tackle important gaps in quality control, sterility testing, and scalable GMP practices. 

Through a networked competence center, the project expands testing capacity, supports ATMP developers, and helps reduce variability in cell-based therapies. By focusing on quality, safety, and efficiency, ATMP XB enables faster, more reliable access to advanced treatments.  

Key Partners 

ATMP XB is co-funded by the European Union under the Interreg Vlaanderen-Nederland programme. 

IDEVAX is a key partner in ATMP XB, contributing alongside a strong cross-border consortium led by Biovia. The partnership includes POM Antwerpen, at.las ATMP, Smart BioMaterials Center (SBMC), anicells, QbD Group, Karel de Grote-Hogeschool, UZ Gent, Anabiotec, RegMed XB, and Sure Laboratories. 

Together, these organizations bring expertise from research, industry, and healthcare to drive innovation and strengthen the ATMP ecosystem.